BeOne Medicines Business Summary

BeOne Medicines Ltd. (NASDAQ: ONC), formerly known as BeiGene, generates the vast majority of its revenue—approximately 99%—through the direct global sale of its proprietary and in-licensed oncology therapeutics. The company’s primary business segments are categorized into Hematology, anchored by its blockbuster BTK inhibitor BRUKINSA (zanubrutinib), and Solid Tumors, led by the anti-PD-1 antibody TEVIMBRA (tislelizumab). BeOne distinguishes itself through a unique "CRO-free" clinical development model, utilizing a massive internal research team of over 1,200 scientists to conduct global trials with higher speed and lower costs than traditional biotech firms. In the competitive oncology landscape, BeOne contends with major pharmaceutical players such as GSK, Sanofi, Takeda Pharmaceutical, and argenex, positioning itself as a high-growth, vertically integrated leader that has successfully transitioned to GAAP profitability as of its fiscal year 2025 results. BeOne was co-founded by John V. Oyler, a serial entrepreneur who serves as Chairman and CEO, and Dr. Xiaodong Wang, a renowned biochemist and member of the National Academy of Sciences who serves as Chairman of the Scientific Advisory Board. The executive leadership team includes President and Global Head of R&D Lai Wang, Chief Financial Officer Aaron Rosenberg, Chief Operating Officer Xiaobin Wu, and Chief Technology Officer Marcello Damiani. The company’s board of directors features high-pedigree industry veterans, including former Sanofi CEO Olivier Brandicourt and former Amgen executive Anthony Hooper. Notable institutional backing remains strong, with Amgen maintaining a strategic 20.5% equity stake alongside significant holdings from HHLR Advisors (Hillhouse) and Baker Brothers, reflecting deep investor confidence in BeOne’s expansive pipeline of next-generation assets like the BCL2 inhibitor sonrotoclax.